Advertisement
U.S. markets open in 2 hours 26 minutes

Sanofi (SAN.PA)

Paris - Paris Delayed Price. Currency in EUR
91.72-0.04 (-0.04%)
As of 11:49AM CET. Market open.
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close91.76
Open91.14
Bid0.00 x 0
Ask0.00 x 0
Day's Range91.07 - 91.72
52 Week Range80.60 - 105.18
Volume155,076
Avg. Volume1,325,052
Market Cap114.488B
Beta (5Y Monthly)0.44
PE Ratio (TTM)21.33
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield3.76 (4.10%)
Ex-Dividend DateMay 13, 2024
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for SAN.PA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Insider Monkey

      32 Countries with the Highest Rates of Diabetes

      In this article, we will be taking a look at the 32 countries with the highest rates of diabetes. If you do not want to learn about the global diabetes market, head straight to the 5 Countries with the Highest Rates of Diabetes. The Global Diabetes Market and Its Implications The global diabetes market is […]

    • Insider Monkey

      Innate Pharma S.A. (NASDAQ:IPHA) Q4 2023 Earnings Call Transcript

      Innate Pharma S.A. (NASDAQ:IPHA) Q4 2023 Earnings Call Transcript March 21, 2024 Innate Pharma S.A. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: At this time, I would like to welcome everyone to the Innate Pharma Full Year 2023 Financial […]

    • Reuters

      Mirador Therapeutics raises over $400 mln in early funding rounds

      Mirador Therapeutics said on Thursday it had secured more than $400 million to develop precision medicines for immune-related diseases, in a rare, large early-stage fundraise. Easing inflationary pressures, increasing bets of a soft landing and promising data from drug trials are starting to boost the biotech funding market, which saw a downturn last year along with other industries. "This is one of the largest series A rounds, probably in history, certainly this year," Mirador CEO and founder Mark McKenna said, without disclosing the valuation at which the funds were raised or the breakdown of the amounts raised in the latest two rounds.